Novo Nordisk (NVO) announced that the Japanese Ministry of Health, Labour and Welfare has approved Ryzodeg for the treatment of diabetes. In Japan, Ryzodeg will be available in FlexTouch, Novo Nordisk's latest prefilled insulin pen, which has an easy auto-injector mechanism, and in Penfill for Novo Nordisk?s durable insulin pens.
Ryzodeg is a soluble formulation of Tresiba, a once-daily newgeneration basal insulin analogue with an ultra-long duration of action, and NovoRapid. Ryzodeg is the first and only soluble insulin combination of Tresiba and the rapid-acting insulin, NovoRapid, providing both fasting and post-prandial glucose control.
Tresiba and Ryzodeg were submitted for regulatory approval to the Japanese Ministry of Health, Labour and Welfare in December 2011 and March 2012, respectively. Tresiba was approved in Japan in September 2012.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.